Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210543 - Datta Jashodeep

  • Investigator:
    Jashodeep Datta
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya

    IRB: 20210543

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Other Digestive Organ

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

    Eligibility Criteria - NCT04559139 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211110 - Ezenwajiaku Nkiruka

  • Investigator:
    Nkiruka Ezenwajiaku
    RCname Email

    Coordinator:
    RCemailImg Natalia Sanders Branca
    RCphone +1 (305) 2433781

    IRB: 20211110

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Pancreas

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    Eligibility Criteria - NCT04858334 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210528 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Natalia Sanders Branca
    RCphone +1 (305) 2433781

    IRB: 20210528

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Pancreas

    Sponsor: Pancreatic Cancer Action Network

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Precision Promise Platform Trial for Metastatic Pancreatic Cancer

    Eligibility Criteria - NCT04229004 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211226 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20211226

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Kidney

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

    Eligibility Criteria - NCT05239728 *This information has been extracted from " www.clinicaltrials.gov"

  • A021806 - Merchant, Nipun

  • Investigator:
    Nipun Merchant
    RCname Email

    Coordinator:
    RCemailImg Natalia Sanders Branca
    RCphone +1 (305) 2433781

    IRB: 20200935

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Pancreas

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer- A021806

    Eligibility Criteria - NCT04340141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20191009

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx

    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers

    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220166 - Sabir Tariq

  • Investigator:
    Tariq Sabir
    RCname Email

    Coordinator:
    RCemailImg Natalia Sanders Branca
    RCphone +1 (305) 2433781

    IRB: 20220166

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Pancreas

    Sponsor: SWOG

    Enrolling Sites:

    Sylvester

    Title:

    Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

    Eligibility Criteria - NCT05040360 *This information has been extracted from " www.clinicaltrials.gov"